No Data
How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.
On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.
Zhongzhi Pharmaceutical Invests in US Biotech Firm to Advance Alzheimer's Treatment
Hong Kong stock market news for December 24: The three major US Indexes closed higher. HKEX has a half-day trading session due to Christmas.
① Consumer confidence in the USA has declined for the first time in three months. ② The three major US stock indices collectively closed higher on Monday, with most China Concept Stocks showing strength. ③ Musk criticized the Federal Reserve, claiming there are absurdly many employees under Powell. ④ The NASDAQ 100 Index is rebalanced, with the weight of Tesla, Meta, and Broadcom decreasing. ⑤ HKEX will have a half-day Trade session on Christmas Eve.
ZHONGZHIPHARM (03737.HK) has signed an investment agreement with the USA Biomedical company GABAeron Inc.
On December 23, Gelonghui reported that ZHONGZHIPHARM (03737.HK) announced that on December 21, 2024, the group held an investment agreement signing ceremony with the USA Biomedical company GABAeron Inc. in Zhongshan. Dr. Huang Yadong, the co-founder and chairman of GABAeron and a renowned neuroscientist, ZHONGZHIPHARM Chairman Lai Zhitian, General Manager Wan Hequn and Deputy General Manager Yu Conghong of Zhongshan Health Base Group Co., Ltd. were present at the event to witness the signing ceremony, along with Vice Presidents Cao Xiao-Jun and Qiao Weilin, Chief Financial Officer Lai Yingsheng, and Lawyer Wang Lifeng.
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
